Long Term Follow-up Results of Brl-201 Phase I Study, a Crispr-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma

被引：1
|
作者：
Zheng, Biao [1 ]
Hu, Yongxian [2 ,3 ,4 ,5 ]
Zhang, Jiqin [1 ]
Zhang, Mingming [2 ,3 ,4 ,5 ]
Li, Wei [1 ]
Wu, Wenjun [2 ,3 ,4 ,5 ]
Cui, Jiazhen [2 ,3 ,4 ,5 ]
Wei, Guoqing [2 ,3 ,4 ,5 ]
Du, Bing [1 ,6 ,7 ]
Liu, Mingyao [1 ,6 ,7 ]
Huang, He [2 ,3 ,4 ,5 ]
机构：
[1] BRL Med Inc, Shanghai, Peoples R China
[2] Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China
[3] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China
[4] Zhejiang Univ, Liangzhu Lab, Med Ctr, Hangzhou, Peoples R China
[5] Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China
[6] East China Normal Univ, Shanghai Frontiers Sci Ctr Genome Editing & Cell, Inst Biomed Sci & Sch Life Sci, Shanghai Key Lab Regulatory Biol, Shanghai, Peoples R China
[7] East China Normal Univ, Sch Life Sci, Shanghai, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185573
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 29 条
  • [1] Long term follow-up results of BRL-201 phase I study, a CRISPR-based non-viral PD-1 locus specific integrated anti-CD19 CAR-T cells in treating relapsed or refractory non-Hodgkin's lymphoma
    Zheng, Biao
    Hu, YongXian
    Zhang, Jiqin
    Zhang, Mingming
    Li, Wei
    Wu, Wenjun
    Cui, Jiazhen
    Wei, Guoqing
    Du, Bing
    Liu, Mingyao
    Huang, He
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study
    Hu, Yongxian
    Zhang, Jiqin
    Zhang, Mingming
    Li, Wei
    Wu, Wenjun
    Cui, Jiazhen
    Wei, Guoqing
    Du, Bing
    Liu, Mingyao
    Huang, He
    BLOOD, 2022, 140 : 7491 - 7492
  • [3] Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in- human phase I study
    Hu, Yongxian
    Zu, Cheng
    Zhang, Mingming
    Wei, Guoqing
    Li, Wei
    Fu, Shan
    Hong, Ruimin
    Zhou, Linghui
    Wu, Wenjun
    Cui, Jiazhen
    Wang, Dongrui
    Du, Bing
    Liu, Mingyao
    Zhang, Jiqin
    Huang, He
    ECLINICALMEDICINE, 2023, 60
  • [4] Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.
    Shah, Nirav Niranjan
    Zhu, Fenlu
    Schneider, Dina
    Taylor, Carolyn
    Krueger, Winfried
    Worden, Andrew
    Longo, Walter L.
    Hamadani, Mehdi
    Fenske, Timothy
    Johnson, Bryon
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r) b-cell non-Hodgkin lymphoma
    Kim, Ki Hyun
    Yoon, Dok Hyun
    Jo, Jae-Cheol
    Jeong, Seong Hyun
    Oh, Sung Yong
    Cho, Hyungwoo
    Choi, Yoon Seok
    Kim, Sung-Hyun
    Lee, Ji Hyun
    Cui, LeiGuang
    Lee, Tae-Bum
    Hwang, In-Sik
    Lee, Young-Ha
    Lee, Yong-Jun
    Lee, Yoon
    Kim, Jong-Hoon
    Lee, Jong-Seo
    Chung, Junho
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] SC-gtCAR19, a Non-Viral Genome Targeting Anti-CD19 CAR-T Candidate in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Updated Results from Long-Term Follow-up
    Wang, Hui
    Gao, Ying
    Zhang, Ding
    Zheng, Yan
    Hu, Xingxing
    Gao, Qiuying
    Niu, Ben
    Hou, Limin
    Wang, Ling
    Zhang, Weihua
    Zhang, Yi
    Ru, Xingli
    Li, Le
    Peng, Zuohan
    Wang, Yi
    BLOOD, 2022, 140 : 4623 - 4624
  • [7] A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial
    Hu, Boyu
    Nastoupil, Loretta J.
    Holmes, Houston
    Hamdan, Ayad
    Kanate, Abraham
    Farooq, Umar
    Cherry, Mohamad
    Brem, Elizabeth
    Pinter-Brown, Lauren C.
    Ermann, Daniel Arthur
    Husnain, Muhammad
    Micklethwaite, Kenneth
    Rizvi, Syed
    Hammad, Ashley
    Thompson, Ben
    Zudaire, Enrique
    Portella, Socorro
    Hamadani, Mehdi
    Essell, James
    O'Brien, Susan Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Clinical results of a first-in-human phase 1 study Bispecific anti-CD19, ANTI-CD20 chimeric antigen receptor modified (LV20.19CAR) T cells for relapsed, refractory, non-Hodgkin lymphoma
    Shah, Nirav
    Zhu, Fenlu
    Keever-taylor, Carolyn
    Schneider, Dina
    Kruger, Winfried
    Worden, Andrew
    Hamadani, Mehdi
    Fenske, Timothy
    Johnson, Bryon
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    BONE MARROW TRANSPLANTATION, 2019, 54 : 123 - 124
  • [9] A phase 1 study of AT101, a novel anti-CD19 CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
    Yoon, Dok Hyun
    Cho, Hyungwoo
    Jo, Jae-Cheol
    Jeong, Seong Hyun
    Oh, Sung Yong
    Kim, Ki Hyun
    Cui, LeiGuang
    Lee, Tae-Bum
    Hwang, In-Sik
    Lee, Young-Ha
    Lee, Yong-Jun
    Kim, Jong-Hoon
    Ruella, Marco
    Lee, Jong-Seo
    Chung, Junho
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)
    O'Brien, Susan
    Nastoupil, Loretta J.
    Essell, James
    Dsouza, Ly
    Hart, Doug
    Matsuda, Emiri
    Satterfield, Tarah
    Nesheiwat, Tonia
    Hammad, Ashley
    Davi, Franco
    Chung, Shally
    Shamsi, S. Asim
    Bryan, Mara
    Skoble, Justin
    Garner, Elizabeth
    Kanner, Steven
    Rizvi, Syed
    Holmes, Houston
    BLOOD, 2022, 140 : 9457 - 9458
123